A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Recruiting

Phase 1

Phase 2

ALE.P02A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Sponsor:

Alentis Therapeutics AG

Code:

NCT06747585

Conditions

Squamous Non-small-cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Cervical Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ALE.P02

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Alentis Therapeutics AG on 2025-05-28.